Antonio Coutinho Madruga Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Antonio Coutinho Madruga Neto has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Guimarães Hourneaux de Moura
Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
3 shared publications - Wanderley Marques Bernardo
Universidade de São Paulo, Brazil
2 shared publications - Ahmad Khan
West Virginia University Robert C Byrd Health Sciences Center Charleston Division, Charleston, West Virginia, USA
1 shared publication - Alberto Machado da Ponte Neto
Gastrointestinal Endoscopy Unit, Hospital das Clínicas, University of Sao Paulo School of Medicine, São Paulo, Brazil
1 shared publication - Antonio Afonso de Miranda Neto
Gastrointestinal Endoscopy Unit, Hospital das Clínicas, University of Sao Paulo School of Medicine, São Paulo, Brazil
1 shared publication - Epifanio Silvino Do Monte Junior
Serviço de Endoscopia Gastrointestinal, Departamento de Gastroenterologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
1 shared publication
Latest Publications
- 27 February 2020
- Published by Springer Nature in Obesity Surgery
- Vol. 30 (5) , 1971-1987
Efficacy and Safety of Endoscopic Sleeve Gastroplasty at Mid Term in the Management of Overweight and Obese Patients: a Systematic Review and Meta-Analysis
Background Endoscopic sleeve gastroplasty (ESG) has emerged as a promising technique in endoscopic bariatric and metabolic therapies (EBMTs). We aimed to perform a systematic review and meta-analysis to provide an update on its efficacy and safety. Methods This is a systematic review and meta-analysis was performed following the PRISMA guidelines. MEDLINE, Cochrane, EMBASE, and LILACS were searched to identify the studies related to ESG. Results Eleven studies with a total of 2170 patients were included. The average BMI pre-ESG was 35.78 kg/m2. Pooled mean %TWL observed at 6, 12, and 18 months was 15.3%, 16.1%, and 16.8% respectively. Pooled mean %EWL at 6, 12, and 18 months was 55.8%, 60%, and 73% respectively. No procedure-related mortality was reported. Conclusion ESG is a safe and effective procedure for primary obesity therapy with promising short- and mid-term results.
- 27 February 2020
- Published by Springer Nature in Obesity Surgery
- Vol. 30 (5) , 1971-1987
Efficacy and Safety of Endoscopic Sleeve Gastroplasty at Mid Term in the Management of Overweight and Obese Patients: a Systematic Review and Meta-Analysis
Background Endoscopic sleeve gastroplasty (ESG) has emerged as a promising technique in endoscopic bariatric and metabolic therapies (EBMTs). We aimed to perform a systematic review and meta-analysis to provide an update on its efficacy and safety. Methods This is a systematic review and meta-analysis was performed following the PRISMA guidelines. MEDLINE, Cochrane, EMBASE, and LILACS were searched to identify the studies related to ESG. Results Eleven studies with a total of 2170 patients were included. The average BMI pre-ESG was 35.78 kg/m2. Pooled mean %TWL observed at 6, 12, and 18 months was 15.3%, 16.1%, and 16.8% respectively. Pooled mean %EWL at 6, 12, and 18 months was 55.8%, 60%, and 73% respectively. No procedure-related mortality was reported. Conclusion ESG is a safe and effective procedure for primary obesity therapy with promising short- and mid-term results.
- 17 October 2018
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 50 (12) , E344-E345
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement
Leaks are serious complications after sleeve gastrectomy, with an incidence rate up to 7 % [1]. Currently, stent placement and other endoscopic techniques are recommended for the treatment of post-bariatric leaks (PBLs) [2]. Bariatric stents are a feasible, effective and life-saving method [3]. They achieve leak closure rates between 72.8 % and 87.8 % but are associated with significant migration rates (16.9 % – 28.2 %) [1] [4]. The large bariatric-specific stent (LBSS) has been developed as an important device to fit bariatric anatomy and avoid migration because of its long length with the distal edge being placed in the duodenum [5]. We report the case of 34-year-old woman who underwent sleeve gastrectomy. On the 5th post-operative day (POD), she developed abdominal pain and purulent output from the drain. Computed tomography (CT) scanning showed a leak at the angle of His without any collections. We opted to place an LBSS (24 cm × 28 mm; Hanarostent, MITECH) to bypass the whole stomach ([Fig. 1]). The LBSS was removed 4 weeks later (33th POD), but the leak persisted. We then placed two single-pigtail stents ([Fig. 2]) and kept them in place for 10 days, but this was also unsuccessful. On the 43 rd POD, we removed the pigtail stents, performed a septotomy, and placed a second LBSS ([Fig. 3]). After 3 weeks (64th POD), the patient again presented with abdominal pain. On this occasion, esophagogastroduodenoscopy (EGD) and upper gastrointestinal series showed complete closure of the leak, but the LBSS could not be seen. A CT scan identified the stent in the proximal jejunum ([Fig. 4]). An enteroscopic attempt to retrieve the stent and 7 days of conservative treatment (laxative, diet, and antispasmodic drug) were unsuccessful, and a laparoscopic enterectomy and primary anastomosis were eventually needed ([Fig. 5]). Finally, 15 days later (86th POD), she was asymptomatic and an EGD showed only a shallow ulcer at the angle of His ([Fig. 6]; [Video 1]). Video 1 Insertion of the first bariatric megastent to treat a leak; removal of the megastent and insertion of two single-pigtail stents; removal of pigtail stents and insertion of a second megastent; the bariatric megastent is found to have migrated into the small bowel and eventually required surgical removal. An LBSS seems to be a useful device for PBL management, but it may cause serious adverse events. Further controlled studies should assess the precise success and complication rates of such stent. Endoscopy_UCTN_Code_CPL_1AH_2AK
- 17 October 2018
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 50 (12) , E344-E345
Stent migration requiring surgical removal: a serious adverse event after bariatric megastent placement
Leaks are serious complications after sleeve gastrectomy, with an incidence rate up to 7 % [1]. Currently, stent placement and other endoscopic techniques are recommended for the treatment of post-bariatric leaks (PBLs) [2]. Bariatric stents are a feasible, effective and life-saving method [3]. They achieve leak closure rates between 72.8 % and 87.8 % but are associated with significant migration rates (16.9 % – 28.2 %) [1] [4]. The large bariatric-specific stent (LBSS) has been developed as an important device to fit bariatric anatomy and avoid migration because of its long length with the distal edge being placed in the duodenum [5]. We report the case of 34-year-old woman who underwent sleeve gastrectomy. On the 5th post-operative day (POD), she developed abdominal pain and purulent output from the drain. Computed tomography (CT) scanning showed a leak at the angle of His without any collections. We opted to place an LBSS (24 cm × 28 mm; Hanarostent, MITECH) to bypass the whole stomach ([Fig. 1]). The LBSS was removed 4 weeks later (33th POD), but the leak persisted. We then placed two single-pigtail stents ([Fig. 2]) and kept them in place for 10 days, but this was also unsuccessful. On the 43 rd POD, we removed the pigtail stents, performed a septotomy, and placed a second LBSS ([Fig. 3]). After 3 weeks (64th POD), the patient again presented with abdominal pain. On this occasion, esophagogastroduodenoscopy (EGD) and upper gastrointestinal series showed complete closure of the leak, but the LBSS could not be seen. A CT scan identified the stent in the proximal jejunum ([Fig. 4]). An enteroscopic attempt to retrieve the stent and 7 days of conservative treatment (laxative, diet, and antispasmodic drug) were unsuccessful, and a laparoscopic enterectomy and primary anastomosis were eventually needed ([Fig. 5]). Finally, 15 days later (86th POD), she was asymptomatic and an EGD showed only a shallow ulcer at the angle of His ([Fig. 6]; [Video 1]). Video 1 Insertion of the first bariatric megastent to treat a leak; removal of the megastent and insertion of two single-pigtail stents; removal of pigtail stents and insertion of a second megastent; the bariatric megastent is found to have migrated into the small bowel and eventually required surgical removal. An LBSS seems to be a useful device for PBL management, but it may cause serious adverse events. Further controlled studies should assess the precise success and complication rates of such stent. Endoscopy_UCTN_Code_CPL_1AH_2AK
- 16 June 2018
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (9) , 2932-2940
The Effectiveness of Endoscopic Gastroplasty for Obesity Treatment According to FDA Thresholds: Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Endoscopic bariatric therapies (EBTs) are promising alternatives to conventional surgery for obesity. The aim of this study is to compare efficacy and safety through a systematic review and meta-analysis of the endoscopic gastroplasty techniques versus conservative treatment. We searched MEDLINE, EMBASE, Cochrane CENTRAL, Lilacs/Bireme. Randomized controlled trials (RCTs) enrolling obese patients comparing endoscopic gastroplasty to sham or diet/exercise were considered eligible. Among 6014 records, three RCTs were selected for meta-analysis. The total sample was 459 patients (312 EBTs vs 147 control). Mean total body weight loss in the intervention group (IG) was 4.8% higher than the control group (CG) at 12 months (p = 0.01). The IG responder rate was 44.31% at 12 months. Therefore, the endoscopic gastroplasty is more effective than conservative therapies but do not achieve FDA thresholds.
- 16 June 2018
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (9) , 2932-2940
The Effectiveness of Endoscopic Gastroplasty for Obesity Treatment According to FDA Thresholds: Systematic Review and Meta-Analysis Based on Randomized Controlled Trials
Endoscopic bariatric therapies (EBTs) are promising alternatives to conventional surgery for obesity. The aim of this study is to compare efficacy and safety through a systematic review and meta-analysis of the endoscopic gastroplasty techniques versus conservative treatment. We searched MEDLINE, EMBASE, Cochrane CENTRAL, Lilacs/Bireme. Randomized controlled trials (RCTs) enrolling obese patients comparing endoscopic gastroplasty to sham or diet/exercise were considered eligible. Among 6014 records, three RCTs were selected for meta-analysis. The total sample was 459 patients (312 EBTs vs 147 control). Mean total body weight loss in the intervention group (IG) was 4.8% higher than the control group (CG) at 12 months (p = 0.01). The IG responder rate was 44.31% at 12 months. Therefore, the endoscopic gastroplasty is more effective than conservative therapies but do not achieve FDA thresholds.